Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation
(AF) is dependent on adherence and persistence in the real-world setting. Individual study …

Introduction Medications cannot exert their effect if not taken as prescribed by patients. Our
objective was to summarise the observational evidence on adherence to oral anticoagulants …

Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke
prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence …

Background Evidence of adherence and persistence patterns in anticoagulation (AC)
therapy comparing treatment‐naïve and non‐naïve patients is lacking. The objective of this …

Background The direct oral anticoagulants (DOACs) reduce the risk of stroke in moderate to
high-risk patients with non-valvular atrial fibrillation (AF). Yet, concerns remain regarding its …

Background and Purpose Data on oral anticoagulant (OAC) uptake and pattern of use are
limited. Real‐life data in patients with atrial fibrillation (AF) are important for understanding …

Aims Studies on adherence and persistence with non-vitamin K oral anticoagulant (NOAC)
treatment have relied on data from the early years of NOAC availability. We aimed to study …

Aims To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant
(NOAC) treatment in patients with atrial fibrillation (AF) in five Western European healthcare …

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Aim To assess persistence and adherence to rivaroxaban, dabigatran, and vitamin K
antagonist (VKA) treatment in primary care patients with non-valvular atrial fibrillation (AF) …